However, hepatic steatosis was ameliorated, rather than increased, following FGF19 or NGM282 treatment of db/db mice, despite increases in Srebf1, Fasn, and Scd1 mRNA levels (Fig. 2D, E). This evidence concerns the gene FGF19 and Hepatic steatosis.